The need for new therapeutics and drug delivery systems has become necessary owing to the public health concern associated with the emergence of multidrug-resistant microorganisms. Among the newly discovered therapeutic agents is cefiderocol, which was discovered by Shionogi Company, Japan as an injectable siderophore cephalosporin. Just like the other β-lactam antibiotics, cefiderocol exhibits antibacterial activity via cell wall synthesis inhibition, especially in Gram negative bacteria (GNB); it binds to the penicillin-binding proteins, but its unique attribute is that it crosses the periplasmic space of bacteria owing to its siderophore-like attribute; it also resists the activity of β-lactamases. Among all the synthesized compounds with the modified C-7 side chain, cefiderocol (3) presented the best and well-balanced activity against multi-drug resistant (MDR) Gram negative bacteria, including those that are resistant to carbapenem. İn this article, an overview of the recent studies on cefiderocol was presented.

由于与多药耐药微生物的出现有关的公共卫生问题，对新疗法和药物输送系统的需求已变得必要。在新发现的治疗剂中有头孢地洛尔，它是由日本盐之木公司发现的一种可注射的铁载体头孢菌素。与其他β-内酰胺类抗生素一样，头孢地洛尔通过抑制细胞壁合成表现出抗菌活性，尤其是在革兰氏阴性细菌（GNB）中。它与青霉素结合蛋白结合，但其独特的特性是由于其铁载体样特性而穿过细菌的周质空间。它也抵抗β-内酰胺酶的活性。在所有具有修饰的C-7侧链的合成化合物中，头孢地洛尔（3）对多重耐药（MDR）革兰氏阴性细菌，包括对碳青霉烯耐药的细菌，表现出最佳且均衡的活性。在本文中，对头孢地洛尔的最新研究进行了概述。